No Photo Available

Last Update

2017-01-04T00:00:00.000Z

This profile was last updated on .

Is this you? Claim your profile.

Wrong David Kleinman?

Dr. David M. Kleinman

Chief Medical Officer

ONL Therapeutics Inc

HQ Phone: (734) 998-8339

Email: d***@***.com

Get ZoomInfo Grow

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

ONL Therapeutics Inc

1600 HURON PKWY

Ann Arbor, Michigan 48109

United States

Company Description

ONL Therapeutics (ONL) is a biopharmaceutical company committed to protecting and improving the vision of patients with a range of retinal diseases and conditions, including retinal detachment and both the wet and dry forms of age-related macular degenera ... more

Find other employees at this company (3)

Background Information

Employment History

Associate Professor of Ophthalmology (Part Time)

Flaum Eye Institute at the University of Rochester

Chief Executive Officer

Eyeon Therapeutics, Inc.

Chief of Ophthalmology

Denver Health

Education

BA

Brown University

Dean's Scholar

Simon School of Business

M.B.A.

M.D.

The University of Rochester Eye Institute

M.D.

University of Rochester Eye Institute - Donald Grover

M.D. with honors

University of Colorado School of Medicine

MBA

Simon School of Business

Web References (36 Total References)


Management – ONL Therapeutics

www.onltherapeutics.com [cached]

David M. Kleinman, M.D., M.B.A., Chief Medical Officer

Dr. Kleinman is a board-certified ophthalmologist with fellowship training in vitreoretinal surgery and more than ten years experience in venture creation and ophthalmic drug and device development. He currently serves as a part-time associated professor ophthalmology at the Flaum Eye Institute at the University of Rochester, where he specializes in the medical and surgical care of patients with retinal disease. David is the former chief of ophthalmology at Denver Health Medical Center, where he also served as an assistant professor of ophthalmology at the Rocky Mountain Lions Eye Institute.
In 2003, he helped found MacuSight, a venture capital backed retinal drug development company, where served as consulting medical director. In his role with MacuSight, David assisted in guiding the company through Series A financing, pre-clinical studies, initial investigational new drug (IND) submission, and Phase I/II clinical development. MacuSight's assets were acquired by Santen in 2010. He holds a bachelor's degree from Brown University, an MBA from the Simon School of Business, and an M.D. with honors from the University of Colorado School of Medicine.


David M. Kleinman, MD, MBA, ...

www.reviewofophthalmology.com [cached]

David M. Kleinman, MD, MBA, Rocherster, N.Y., and David N. Zacks, MD, PhD, Ann Arbor, Mich.

...
Dr. Kleinman is a part-time associate professor of ophthalmology at the Flaum Eye Institute at the University of Rochester where he specializes in the medical and surgical care of patients with retinal disease. He has spent more than 10 years working in retinal pharmaceutical development and currently serves as the chief medical officer at ONL Therapeutics Inc.


Eyeon Therapeutics Out-Licenses Proprietary OTC Dry Eye Product

www.prnewswire.com [cached]

David Kleinman, MD, CEO of Eyeon Therapeutics commented, "We are grateful to Particle Sciences for their support in helping us develop and advance this important new technology designed to provide a better treatment opportunity for dry eye patients, and we are delighted to have found an excellent commercial organization to bring this technology to patients with dry eye disease in North America.


David Kleinman, Associate ...

ois.net [cached]

David Kleinman, Associate Professor of Ophthalmology - Flaum Eye Institute


ONL Therapeutics Announces Management Team Additions – ONL Therapeutics

www.onltherapeutics.com [cached]

The company has appointed David Kleinman, M.D. as chief medical officer and Linda Johnson as senior vice president of operations, bringing significant industry experience to ONL in the area of ocular drug development.

...
Dr. Kleinman is also a retina specialist and has spent over ten years in venture creation and ophthalmic drug and device development. He currently serves as part-time associate professor of ophthalmology on the retina service at the Flaum Eye Institute at the University of Rochester. Previously, Dr. Kleinman helped found MacuSight, a venture capital backed retinal drug development company, where he served as consulting medical director. In his role with MacuSight David assisted in guiding the company through Series A financing, pre-clinical studies, investigational new drug (IND) submission, and Phase I/II clinical development. David has extensive experience consulting for both small and large ophthalmic companies in clinical trial design and execution, regulatory interaction, drug safety monitoring, and the evaluation and advancement of novel ophthalmic technology.

Similar Profiles

Other People with this Name

Other people with the name Kleinman

Kevin Kleinman
Salesforce.Com Inc

Kenneth Kleinman
Stevens & Lee P.C

Megan Kleinman
Catholic Charities Brooklyn & Queens

David Kleinman
The DARBY GROUP

Ella Kleinman
Exact Data ConsumerBase LLC

City Directory Icon

Browse ZoomInfo's Business Contact Directory by City

People Directory Icon

Browse ZoomInfo's
Business People Directory

Company Directory Icon

Browse ZoomInfo's
Advanced Company Directory